Therapeutic approaches to induce major histocompatibility complex I expression on cancer cells by MEK inhibitors in order to improve immune-checkpoint blockade efficacy have not resulted in better clinical outcome in metastatic CRC [33]. This evidence concerns the gene MAP2K7 and cancer.